Highlights from 16th European Multidisciplinary Congress on Urological Cancers – EMUC24
The 16th European Multidisciplinary Congress on Urological Cancers (EMUC24) took place in Lisbon, Portugal, from 7 to 10 November 2024.
Top experts in medical oncology, pathology, radiation oncology, radiology, nuclear medicine, and urology gathered at the congress to share their insights on best practices, developments in major trials, and recent breakthroughs. Throughout the event, the EMUC24 scientific programme featured in-depth lectures, practical hands-on training courses, and engaging multidisciplinary case discussions.
EMUC24 highlighted cutting-edge therapies, examined current practices, addressed controversies, and explored emerging technologies in the field of urological cancers. The multidisciplinary nature of the congress was made possible through the strong collaboration of the European Society for Medical Oncology (ESMO), the European Society for Radiotherapy and Oncology (ESTRO), and the European Association of Urology (EAU).
The congress also partnered with the Kidney Cancer Association (KCA), providing vital insights into the latest developments in kidney cancer treatment. EMUC24 offered an excellent platform to discover what’s new and crucial in genitourinary cancer treatment, bringing together leading experts and fostering important discussions.
ESR EU & International Affairs:
“On this special day for radiology, ESR PAG member Erik Briers gave a presentation on prostate cancer screening from the patient’s perspective at the opening of the EMUC2024 congress.”
“At Lisbon attending the EMUC2024 to participate at the board meeting of
Europa UOMO.”
“Glad to present for the first time at EMUC2024 our BRIDGEAI Study 3! This project explores creating automatic lay abstracts and summaries with built-in fact-checking, making complex info more accessible and reliable.”
“Opening program EMUC2024 co chaired by Morgan Roupret, Elena Castro, Alison Tree starting with AI session in healthcare . Join us for an exciting morning discussing all aspects of integration of AI in oncology.”
“PET-PSMA stratification in high and low risk, had a direct implication in overall survival in all scenario, validating a very well done nomogram.”
“Engaging rapid-fire debate on kidney cancer management at EMUC2024! Experts tackled challenges in surgery, systemic therapies, and the role of SBRT. Great insights into the future of personalized care.”
“Amazing opening of EMUC2024 in Lisbon! Kudos to Veeru Kasi from UK for his insightful talk on ‘What challenges for urologists?’ as part of Current challenges for the organised screening programmes in the ESUI Plenary session.”
“mHSPC patient with profound PSA response : panel would propose de-escalation therapy!”
“EORTC 1414 PEGASUS trial: Degarelix combined with EBRT shows a reduction in the risk of CV events compared to LHRH agonists in pts with previous CV disease EMUC2024 Bertrand TOMBAL, Pedro Lara and Dirk Boehmer and all PEGASUS investigator.”
“EMUC2024 very relevant and promising data with the use of PETPSMA in the scenario of rebiopsy of prostate cancer, very good effort lead by Giovanni Lughezzani.”
More posts like this on oncodaily.com
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023